PT3552619T - Polipéptidos de fator ix e métodos de uso dos mesmos - Google Patents

Polipéptidos de fator ix e métodos de uso dos mesmos

Info

Publication number
PT3552619T
PT3552619T PT191560747T PT19156074T PT3552619T PT 3552619 T PT3552619 T PT 3552619T PT 191560747 T PT191560747 T PT 191560747T PT 19156074 T PT19156074 T PT 19156074T PT 3552619 T PT3552619 T PT 3552619T
Authority
PT
Portugal
Prior art keywords
polypeptides
factor
methods
Prior art date
Application number
PT191560747T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3552619(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of PT3552619T publication Critical patent/PT3552619T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT191560747T 2010-07-09 2011-07-11 Polipéptidos de fator ix e métodos de uso dos mesmos PT3552619T (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36306410P 2010-07-09 2010-07-09
US201061424555P 2010-12-17 2010-12-17
US201161430819P 2011-01-07 2011-01-07
US201161438572P 2011-02-01 2011-02-01
US201161442079P 2011-02-11 2011-02-11
US201161470951P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
PT3552619T true PT3552619T (pt) 2025-10-23

Family

ID=45441870

Family Applications (1)

Application Number Title Priority Date Filing Date
PT191560747T PT3552619T (pt) 2010-07-09 2011-07-11 Polipéptidos de fator ix e métodos de uso dos mesmos

Country Status (23)

Country Link
US (13) US9670475B2 (enExample)
EP (3) EP2590668A4 (enExample)
JP (5) JP2013534426A (enExample)
KR (5) KR20230156435A (enExample)
CN (1) CN103140237A (enExample)
AU (5) AU2011274414B2 (enExample)
BR (1) BR112013000650A8 (enExample)
CA (1) CA2804274A1 (enExample)
CL (1) CL2013000058A1 (enExample)
DK (1) DK3552619T3 (enExample)
EA (2) EA028067B1 (enExample)
FI (1) FI3552619T3 (enExample)
IL (3) IL223990B (enExample)
LT (1) LT3552619T (enExample)
MX (3) MX375112B (enExample)
MY (2) MY166954A (enExample)
NZ (1) NZ605348A (enExample)
PL (1) PL3552619T3 (enExample)
PT (1) PT3552619T (enExample)
RS (1) RS67366B1 (enExample)
SG (3) SG186856A1 (enExample)
UA (2) UA126265C2 (enExample)
WO (1) WO2012006624A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
PL3453402T3 (pl) 2012-01-12 2022-03-21 Bioverativ Therapeutics Inc. Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP2836518B1 (en) 2012-04-11 2019-01-02 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
TW201427685A (zh) * 2012-09-25 2014-07-16 Biogen Idec Inc Ｆｉｘ多肽的應用
CA2888806A1 (en) * 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
AU2013348029A1 (en) * 2012-11-20 2015-07-02 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX proteins
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
LT2956477T (lt) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimizuotas faktoriaus viii genas
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EA037906B1 (ru) * 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
CA2934081A1 (en) * 2013-12-23 2015-07-02 Csl Limited Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
SG10201913735SA (en) * 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
EP3481416B1 (en) 2016-07-08 2020-09-09 CSL Behring Lengnau AG Subcutaneous administration of long-acting factor ix in humans
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US11045128B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter for monitoring intra-abdominal pressure
US10813589B2 (en) 2017-06-03 2020-10-27 Sentinel Medical Technologies, LLC Catheter for monitoring uterine contraction pressure
US11045143B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter with connectable hub for monitoring pressure
US10799131B2 (en) 2017-06-03 2020-10-13 Sentinel Medical Technologies, LLC Catheter for monitoring intrauterine pressure to protect the fallopian tubes
US11185245B2 (en) 2017-06-03 2021-11-30 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure for muscle compartment syndrome
CN110799209A (zh) * 2017-06-29 2020-02-14 康诺贝林伦瑙有限公司 用于预防性治疗血友病的包含因子ix和人白蛋白的融合蛋白的21天给药方案及其方法
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
CN119955796A (zh) 2018-08-09 2025-05-09 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US11672457B2 (en) 2018-11-24 2023-06-13 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
US11779263B2 (en) 2019-02-08 2023-10-10 Sentinel Medical Technologies, Llc. Catheter for monitoring intra-abdominal pressure for assessing preeclampsia
WO2020187969A1 (en) 2019-03-19 2020-09-24 CSL Behring Lengnau AG Factor ix variants and uses thereof in therapy
EP3956456A1 (en) 2019-04-17 2022-02-23 Codiak BioSciences, Inc. Compositions of exosomes and aav
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
WO2021026020A1 (en) 2019-08-08 2021-02-11 Sentinel Medical Technologies, LLC Cable for use with pressure monitoring catheters
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
US11617543B2 (en) 2019-12-30 2023-04-04 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
EP4362971A1 (en) * 2021-07-01 2024-05-08 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1995021258A1 (en) 1994-02-01 1995-08-10 United States Of America, Represented By The Secretary, Department Of Health And Human Services Fusion proteins that include antibody and nonantibody portions
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
ATE238668T1 (de) 1995-01-17 2003-05-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelialer transport von immunogenen
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ATE455552T1 (de) 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
BR9815975A (pt) 1998-07-31 2001-12-04 Wallace E Carroll Método e aparelho para a determinação defatores de terapia anticoagulante
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
DK1278763T3 (da) 2000-04-28 2007-06-11 Inflazyme Pharm Ltd 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
CN1547608A (zh) 2001-09-04 2004-11-17 Ĭ��ר�����޹�˾ 经修饰的因子ix
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
KR101204712B1 (ko) * 2003-03-18 2012-11-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Ｇｌａ-잔기 함유 세린 프로테아제의 제조 방법
JP2007524607A (ja) 2003-04-09 2007-08-30 ワイス 凝固因子の吸入による血友病処置
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US7212798B1 (en) * 2003-07-17 2007-05-01 Cisco Technology, Inc. Adaptive AGC in a wireless network receiver
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
EP1673395A1 (en) * 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
NZ546733A (en) 2003-12-03 2009-07-31 Novo Nordisk As Glycopegylated factor IX
JP2008509688A (ja) 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンｋ依存性ポリペプチド
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090100533A1 (en) 2004-12-21 2009-04-16 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems
US20060162552A1 (en) 2005-01-26 2006-07-27 Mohawk Valley Energy Solutions, Inc. Systems and methods for controlling room air quality
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
ES2749574T3 (es) 2005-11-01 2020-03-23 Wyeth Llc Solución de cloruro sódico para la reconstitución de fármacos
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
HUE067285T2 (hu) 2006-03-24 2024-10-28 Bioverativ Therapeutics Inc PC5 mint IX-es faktor propeptidet feldolgozó enzim
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
BRPI0712008A2 (pt) 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag derivados e análogos de fix prolongados
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
JP5122562B2 (ja) 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
WO2008022151A1 (en) 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
AU2007293614A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
CN104004739A (zh) 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
AU2009244633A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified Factor IX polypeptides and uses thereof
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
EP2280734B1 (en) * 2008-04-24 2014-02-26 Cantab Biopharmaceuticals Patents Limited Factor ix conjugates with extended half-lives
US20090282865A1 (en) 2008-05-16 2009-11-19 Ortloff Engineers, Ltd. Liquefied Natural Gas and Hydrocarbon Gas Processing
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
GB2479069B (en) 2008-09-24 2012-07-25 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
WO2011030641A1 (ja) 2009-09-08 2011-03-17 コニカミノルタホールディングス株式会社 身体用装具
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
CN103140237A (zh) * 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
TW201427685A (zh) 2012-09-25 2014-07-16 Biogen Idec Inc Ｆｉｘ多肽的應用
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
CA2934081A1 (en) 2013-12-23 2015-07-02 Csl Limited Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof

Also Published As

Publication number Publication date
SG10201913700SA (en) 2020-03-30
CL2013000058A1 (es) 2014-03-28
AU2011274414A1 (en) 2013-01-24
JP2017036328A (ja) 2017-02-16
EP4653528A2 (en) 2025-11-26
NZ605348A (en) 2015-01-30
MX356527B (es) 2018-06-01
KR20230156435A (ko) 2023-11-14
US9867873B2 (en) 2018-01-16
AU2022204643A1 (en) 2022-07-21
JP2016034973A (ja) 2016-03-17
WO2012006624A2 (en) 2012-01-12
MX2013000281A (es) 2013-03-22
US20160346365A1 (en) 2016-12-01
US10898554B1 (en) 2021-01-26
KR20190104442A (ko) 2019-09-09
PL3552619T3 (pl) 2025-12-01
US20190192640A1 (en) 2019-06-27
EA037095B1 (ru) 2021-02-05
IL277432B (en) 2021-07-29
US10561714B2 (en) 2020-02-18
KR20140017480A (ko) 2014-02-11
RS67366B1 (sr) 2025-11-28
IL277432A (en) 2020-11-30
CN103140237A (zh) 2013-06-05
FI3552619T3 (fi) 2025-11-05
DK3552619T3 (da) 2025-10-20
AU2011274414B2 (en) 2016-10-06
UA115120C2 (uk) 2017-09-25
US20160257943A1 (en) 2016-09-08
US20160166657A1 (en) 2016-06-16
AU2017268650B2 (en) 2019-10-10
AU2016228243A1 (en) 2016-10-06
US9675676B2 (en) 2017-06-13
EP2590668A4 (en) 2014-04-02
AU2016228243B2 (en) 2017-08-31
IL223990B (en) 2020-10-29
JP2022044828A (ja) 2022-03-17
EP3552619B1 (en) 2025-07-30
US9629903B2 (en) 2017-04-25
AU2020200118A1 (en) 2020-01-30
US20130202595A1 (en) 2013-08-08
EA201790876A1 (ru) 2017-12-29
MX2020009702A (es) 2020-10-07
US20160243206A1 (en) 2016-08-25
US9233145B2 (en) 2016-01-12
AU2020200118B2 (en) 2022-04-07
UA126265C2 (uk) 2022-09-14
KR20220097518A (ko) 2022-07-07
EP2590668A2 (en) 2013-05-15
EA028067B1 (ru) 2017-10-31
MX375112B (es) 2025-03-06
JP2013534426A (ja) 2013-09-05
US10548954B2 (en) 2020-02-04
EP3552619A1 (en) 2019-10-16
US20210023185A1 (en) 2021-01-28
US10568943B2 (en) 2020-02-25
IL284368A (en) 2021-07-29
JP2019023242A (ja) 2019-02-14
US9670475B2 (en) 2017-06-06
SG10201505218YA (en) 2015-08-28
US20130171175A1 (en) 2013-07-04
SG186856A1 (en) 2013-02-28
LT3552619T (lt) 2025-11-10
EA201291480A1 (ru) 2013-09-30
US20190192641A1 (en) 2019-06-27
BR112013000650A2 (pt) 2016-05-31
US20210008178A1 (en) 2021-01-14
MY166954A (en) 2018-07-25
BR112013000650A8 (pt) 2017-10-17
MY192639A (en) 2022-08-29
AU2022204643B2 (en) 2025-08-28
US20180228878A1 (en) 2018-08-16
US20180207244A1 (en) 2018-07-26
AU2017268650A1 (en) 2017-12-21
KR20180118808A (ko) 2018-10-31
US20180228879A1 (en) 2018-08-16
CA2804274A1 (en) 2012-01-12
US9623091B2 (en) 2017-04-18
WO2012006624A3 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
IL284368A (en) Factor ix polypeptides and methods of using them
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
EP2791333A4 (en) OPSINE POLYPEPTIDES AND METHODS OF USE
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL247595A0 (en) New modulators and methods of use
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
PT2539326T (pt) Ariltriazolonas ligadas a bisaril e sua utilização
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
ZA201209205B (en) Pyridone and aza-pyridone compounds and methods of use
IL222027A (en) Peptides and their use
SG10201601792UA (en) Novel modulators and methods of use
SI2523678T1 (sl) Antagonisti Wnt in postopki zdravljenja
ZA201208770B (en) New forms of rifaximin and uses thereof
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
WO2011140391A9 (en) Egfr-related polypeptides and methods of use
SG173752A1 (en) Modifications of cupredoxin derived peptides and methods of use thereof
IL222714A0 (en) Preparation of polypeptides and salts thereof
EP2611459A4 (en) POLYPEPTIDES DERIVED FROM ALPHA-1-ANTITRYPSIN AND METHOD FOR THEIR USE
PL2558485T3 (pl) Antygeny polipeptydowe z trichinella i ich zastosowania
ZA201007681B (en) Cd4-related polypeptides and methods of use
GB201015385D0 (en) Socket cover and method of use thereof